ArticleFrontiers in public health2026
Burden of dermatology outpatient and inpatient services in China, 2011-2023.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to describe the temporal trends, regional distribution of dermatology services, and the hospitalization burden of common skin diseases in China (2011-2023) and provide reference for the government about resource allocation. Methods: Data on dermatology outpatient visits and discharges from public hospitals by age and provinces were sourced from Results: From 2011 to 2023, the total number of dermatology outpatient visits and inpatient discharges from public hospitals in China were 1.36 billion and 7.38 million, respectively. Both the number and rate of outpatient and inpatient increased until 2019, declined in 2020, and rebound after 2021. Outpatient visits were highest in the eastern region, whereas inpatients were highest in the western region. The top five provinces for total outpatient visits were Guangdong, Zhejiang, Jiangsu, Shanghai, and Sichuan, for inpatient discharges from public hospitals: Hubei, Sichuan, Shandong, Guangdong, and Henan. Among four skin diseases, eczema/dermatitis had the most hospitalizations (1,209,754), followed by urticaria (719,610), benign skin tumors (653,036), and psoriasis (370,409). Total hospitalization cost for the four diseases was 14.66 billion RMB, with eczema/dermatitis accounting for the largest share (6.23 billion). Psoriasis had the longest hospital stay (median 11.58 days) and highest cost (median 8,880.66 RMB) per patient. Hospitalized for benign skin tumors, psoriasis, eczema/dermatitis, and urticaria were mainly in the 15-44, 15-44, ≥60 and 5-44 age group, respectively. Conclusion: The burden of skin diseases in China showed an increased trend before the COVID-19 pandemic. Dermatology service in China showed an east-west inverse pattern between outpatient and inpatient care. Resource allocation should consider both outpatient and inpatient data. Eczema/dermatitis had the highest hospitalization burden, while psoriasis had the longest stays and highest costs. Meanwhile, age-stratified strategies should be implemented in skin diseases clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.